Skip to content
FY'25FY'24FY'23FY'22
Profitability
Gross margin89.6%+1.4pp88.2%+2.0pp86.2%-0.7pp86.9%-0.1pp
Operating margin-8.7%-21.0pp12.3%+13.2pp-0.9%-7.8pp6.9%-7.9pp
Net margin-5.4%-16.5pp11.2%+10.9pp0.2%-8.9pp9.1%-0.1pp
Returns
Return on equity-3.7%-11.2pp7.5%+7.4pp0.1%-7.0pp7.1%+0.3pp
Return on invested capital-6.3%-12.8pp6.5%+7.1pp-0.6%-5.5pp4.9%-3.1pp
Efficiency
Asset turnover0.5×0.0×0.5×+0.1×0.4×0.0×0.4×0.0×
Liquidity
Current ratio1.9×-0.4×2.3×+0.6×1.7×+0.6×1.1×-0.8×
Leverage
Debt-to-equity0.0×0.0×0.0×-0.5×
Net debt / EBITDA-3×-2.8×-0.2×+0.2×-0.4×0.0×-0.4×-2.3×
Per Share
Book value per share$18.81+1.6%$18.51+11.5%$16.60+15.5%$14.37-4.3%
Valuation
Market capitalization$2.85B+42.7%$2B+26.3%$1.58B-18.1%$1.93B+11.5%
Price / sales+0.9×+0.4×2.6×-0.3×2.9×-0.1×
Price / book2.7×+0.8×1.9×+0.2×1.7×-0.5×2.2×+0.1×
EV / EBITDA94.3×+82.2×12.1×-7.3×19.4×+5.2×14.3×-2.2×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Supernus Pharmaceuticals's profit margins?
Supernus Pharmaceuticals (SUPN) runs a 89.4% gross margin and a -7.8% operating margin, with a -3.7% net margin.
Where do Supernus Pharmaceuticals's ratios come from?
Every ratio is computed from Supernus Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.